Zimmer Biomet (ZBH) Stock: Buy, Sell, or Hold?
ZBH - Zimmer Biomet Holdings, Inc.
$94.86
-1.14 (-1.19%)
âŧ
5d:
+3.37%
30d:
+0.94%
90d:
+5.81%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When ZBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ZBH is fairly priced but lacks strong directional signals. At 0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ZBH is fairly priced but lacks strong directional signals. At 0.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$119.28
Based on 5.1% avg growth
INTRINSIC VALUE TODAY
$74.06
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZBH is currently trading at $94.86, which is considered slightly high relative to its 30-day fair value range of $89.54 to $95.34. The stock's valuation (Forward PE: 10.5) is in line with its historical norms (10.3). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ZBH is in a uptrend. The price is approaching resistance at $97.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZBH scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $106.90 (+12.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZBH is in a uptrend. The price is approaching resistance at $97.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZBH scores 18/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $106.90 (+12.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$89.54 -
$95.34
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.4%
Protect Your Profits
Holding ZBH? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (18/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($106.90)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$89.54 -
$95.34
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$87.31
Resistance Level
$97.00
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.48
Wall Street Target
$106.90
(+12.7%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
33.8%
Profit Margin
9.5%
Valuation Premium vs History
+0.7% premium
PE vs Historical
10.5 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$95.52
(+1%)
2-Year Target
$96.19
(+1%)
3-Year Target
$96.87
(+2%)
3-Yr Target (if PE normalizes)
(PE: 10â10)
PE COMPRESSION
$95.22
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 6.1%)
$214.64
(+126%)
Base:
(SPY PE: 10.5, Growth: 6.1%)
$113.24
(+19%)
Bear:
(PE: 8.9, Growth: 6.1%)
$96.26
(+2%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 23.30 | Current EPS (TTM): $4.12
Bull Case
$211.20
(+123%)
Analyst growth 100.0%, PE expands to 25.6
Base Case
$192.00
(+102%)
Market implied 100.0%, PE stable at 23.3
Bear Case
$65.28
(-31%)
Severe decline -20.0%, PE contracts to 19.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 21, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 43 HOLD |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 75 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 54 HOLD |
Advanced ZBH Option Strategies
Professional options setups generated by AI based on today's ZBH price and gamma walls.
